BetterLife Pharma Inc. is an emerging biotechnology company primarily focused on developing and commercializing a compound, BETR-001, to treat neuro-psychiatric and neurological disorders.

BETR-001, which is in preclinical and IND-enabling studies, is a non-hallucinogenic and non-controlled LSD derivative in development and it is unique in that it is unregulated and therefore can be self-administered. BetterLife’s synthesis patent for BETR-001 eliminates regulatory hurdles and its pending patent for composition and method of use covers treatment of depression, cluster headaches, post-traumatic stress disorder and other neuro-psychiatric and neurological disorders.

BetterLife also owns a drug candidate for the treatment of viral infections  and is in the process of seeking strategic alternatives for further development.